Tot Biopharm attracts $102 mln Series B
Tot Biopharm, a Chinese maker of anti-tumor drugs, has raised $102 million in Series B funding. The investors included China Universal (Cayman) GP Limited, Center Laboratories Group, Vivo Capital, Chengwei Capital, Yuanta Financial Holdings Group and Cathay Capital.
10 August 2018•1 min read
